Denosumab in men receiving androgen-deprivation therapy for prostate cancer - sprookjes - yvandenbroek - TriplyDB

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

http://www.wikidata.org/entity/Q34570396

about

Bisphosphonates for preventing and treating osteoporosis in men Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality The role of RANK-ligand inhibition in cancer: the story of denosumab Opportunities to maximize value with integrated palliative care Bone Metastasis from Renal Cell Carcinoma Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer Managing breast cancer in younger women: challenges and solutions Prevention and treatment of bone fragility in cancer patient Male Osteoporosis in the Elderly Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients New drugs for prostate cancer Management of patients with biochemical recurrence after local therapy for prostate cancer Nuclear receptors in bone physiology and diseases Targeting bone physiology for the treatment of metastatic prostate cancer Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences Treatment of primary osteoporosis in men Screening, diagnosis and treatment of osteoporosis: a brief review Management of endocrine disease: Secondary osteoporosis: pathophysiology and management Denosumab for the treatment of osteoporosis Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer Recent progress in pharmaceutical therapies for castration-resistant prostate cancer Increasing options for the treatment of osteoporosis 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary RANKL/RANK-beyond bones Mechanisms of action of therapeutic antibodies for cancer Recent Clinical Trials in Osteoporosis: A Firm Foundation or Falling Short?Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.Radium-223 dichloride in clinical practice: a review.Food Fortification and Supplement Use-Are There Health Implications?Role of denosumab in prostate cancer.Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.Next generation of antibody therapy for cancer.Future of bisphosphonates and denosumab for men with advanced prostate cancer.Update in male osteoporosis.Recent advances in bone-targeted therapies of metastatic prostate cancer Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.Bone-targeting agents in prostate cancer.

P2860

Q24197612-152D8CDE-34E1-49AE-B6F2-6834FBA84AD1 Q24597422-FF66D30C-1ACE-4DDB-974D-A127A7AC2984 Q24623768-C918C820-1D17-4CC4-A775-73F5B33FD9F3 Q24633284-51221E0E-3504-464D-9E33-0A22A9F5698C Q26745944-CF1D7389-1751-407B-AD35-BD0550896573 Q26747493-7AAE8E9D-0C13-4CED-80C8-58807599AAA0 Q26747782-D0316E0C-6E4B-47EB-A158-7AA692D00CDC Q26752785-DA59E283-A077-4033-8683-2842111B8C7B Q26771184-8C3CA8E6-9F96-46FA-AB91-BBFD87904CBA Q26775765-BC0E13EE-1E1B-4D06-975D-C202849445AF Q26784352-A1DD5406-58F9-4488-ACD9-4B8A7DAB34B5 Q26824762-A474648E-4695-4844-AD56-2013FAADFDEC Q26827515-8C26066C-66D7-416A-AEFE-DBB179B2CA56 Q26849220-EA067575-3A76-4DA9-BC82-67DEEED76B59 Q26853017-25CDFD9E-8AE1-4601-9C74-E3BBDF1A50CA Q26863249-30B4D0BE-7A39-4C4A-8B88-0A85EDFD063A Q26863493-2B9986DF-D07A-487D-B71A-B45C20439268 Q26991748-E85E90A5-B7DF-4756-9004-C8CD12199DA5 Q26996726-6B461A12-D724-424A-9F3C-9C376A3D77DB Q26998249-8C997EF2-F082-4E4D-BEB6-846149C75549 Q27009275-94D41824-EEE2-4B95-AB16-8E88915660C4 Q27021268-912B23F3-EC6E-4EB0-9B04-C3E18F44291B Q27022567-6EAF11A4-52CE-4BBE-8871-3CC66DD2973F Q28254516-7318151A-24DC-40E6-A411-863A93CBA513 Q28295416-A0F57DFD-3D81-46D2-8F78-AC448F63E892 Q28308042-C10186A3-510C-4B92-BDC6-7FD5C19312BA Q28385366-CB88FE64-66CC-4689-8CF0-0BBA98702719 Q28552191-0A206B9D-23F0-499E-B497-569029F16B9C Q30235173-60ACFF3F-721C-45C2-AED3-05D42B5FAEC9 Q30251496-C55A5E05-8619-45E0-82CC-1512079FFB95 Q30252188-7F5D11B3-F8C6-49DC-9443-26879EC2DCF4 Q30455154-54E13FFA-4FF9-467F-8FE4-659C8D3992D5 Q33441667-83ABB5C8-2796-44DD-9D5F-5E36ECDB643F Q33579636-EB2A97FF-A1CF-4FEF-8E29-E31BF32B5E88 Q33583525-4BB355AD-0E22-4D9E-A3F6-EC648A41D96A Q33586703-7F2FAE05-66A6-4706-8D12-570A87867AE2 Q33703763-5BB78FF7-4E55-4643-82F6-0C852628720F Q33754036-9D498FFA-553A-4465-992A-C3F2D57E105F Q33789201-9CBA4549-C7BD-4261-8327-8CC2F35287F7 Q33864723-2A81B81C-3BE1-4B5C-ACBD-4BF83299BE00

P2860

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

http://www.wikidata.org/entity/Q34570396

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

@ast

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

@en

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

@nl

type

label

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

@ast

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

@en

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

@nl

prefLabel

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

@ast

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

@en

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

@nl

P1433

Q34570396-47B72B61-FD64-400D-994B-9B2BA69EAB25

P1476

Q34570396-CDA59381-FA11-4F79-B187-6F34A76A6274

P2093

Q34570396-05BDA65A-7C2D-45BF-AD91-E463208F23E9

Q34570396-209BBFD9-4023-4840-AEEE-0DBEA733104F

Q34570396-5527420B-9A8E-4661-AD6B-1BFE9B9DBB17

Q34570396-57BB9D53-C629-4D4D-ADD0-69BCF515E395

Q34570396-650BB8B7-50CA-4985-BE0F-2DBAC4091262

Q34570396-6E9BCACA-C028-41C6-8ABF-2AB90152F281

Q34570396-7411A6ED-FD86-4682-B0F1-BD6B19C96037

Q34570396-841DD211-D615-433F-B696-6D23BDB6704A

Q34570396-C16E3007-905F-488D-B09F-5492A3BB1D5D

Q34570396-C1791618-42F1-40F9-BE4D-E80482C41068

P2860

Q34570396-13E2C4E2-9CFD-4DF4-AEEA-CE198BC0DDEA

Q34570396-160AA957-DAF6-4AFA-AC8C-B9740B9EDA3D

Q34570396-1B47532B-67DF-4408-A1C6-C6603C6D7BF5

Q34570396-228CA316-072E-456F-9CE0-7F61CAC2BA44

Q34570396-428567A0-E1AE-43F7-B699-AABFE8E4D0B7

Q34570396-4A6AC1CE-6A0D-47C7-9049-F482FE0BCF07

Q34570396-56189982-7086-4B0D-B5D7-3A01533BAA0F

Q34570396-5DD58D48-C090-486C-A2EA-6265253A8C3A

Q34570396-630C1D31-4E0C-4954-9B46-EAB73D3E1F56

Q34570396-6738FC20-D1FA-444E-A198-6EE10A408C23

P304

Q34570396-1F60EB38-A9ED-4662-984F-EA0DB2F81A14

P31

Q34570396-484BB6CB-E0F6-48E5-88B3-2EED9EFEAC72

P356

Q34570396-70E8FB7C-A53C-498D-B3CC-A3B87A835E35

P407

Q34570396-166EF589-D898-4D64-AD64-FD0415138F77

P433

Q34570396-F1E1471F-87D7-4FFF-B6D2-873F010E177E

P478

Q34570396-F838870F-8425-40B9-9883-834DB24C2C46

P50

Q34570396-E77E1F4B-EFD1-485C-AC4A-C573D31B596C

P577

Q34570396-0B2CA652-1301-4876-9089-B4AB8165E6C7

P5875

Q34570396-6D1E7733-5C6D-407E-BBA7-16AE94E68D55

P698

Q34570396-F6FE00BB-6C71-42B8-8DA5-1BEF48E7A27B

P932

Q34570396-086DF20A-12FE-4B8A-B64A-43389BAF1F0A

P356

P1433

The New England Journal of Medicine

P1476

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

@en

P2093

Amy Kupic

http://www.w3.org/2001/XMLSchema#string

Benjamin Z Leder

http://www.w3.org/2001/XMLSchema#string

Blair Egerdie

http://www.w3.org/2001/XMLSchema#string

Carsten Goessl

http://www.w3.org/2001/XMLSchema#string

Chunlei Ke

http://www.w3.org/2001/XMLSchema#string

Denosumab HALT Prostate Cancer Study Group

http://www.w3.org/2001/XMLSchema#string

Fred Saad

http://www.w3.org/2001/XMLSchema#string

Maciej Szwedowski

http://www.w3.org/2001/XMLSchema#string

Matthew R Smith

http://www.w3.org/2001/XMLSchema#string

Narciso Hernández Toriz

http://www.w3.org/2001/XMLSchema#string

P2860

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

Global cancer statistics, 2002

Cancer statistics, 2008

Denosumab in postmenopausal women with low bone mineral density

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study.

Is it ethical to conduct placebo-controlled clinical trials in the development of new agents for osteoporosis? An industry perspective.

Androgen deprivation therapy for prostate cancer.

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.

P304

745-755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0809003

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

361

http://www.w3.org/2001/XMLSchema#string

P50

Jiří Heráček

P577

2009-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26733164

http://www.w3.org/2001/XMLSchema#string

P698

19671656

http://www.w3.org/2001/XMLSchema#string

P932

3038121

http://www.w3.org/2001/XMLSchema#string